% | $
Quotes you view appear here for quick access.

VPHM Message Board

  • laonda32 laonda32 May 9, 2013 5:56 AM Flag


    pls check the propthink article I have posted before:
    Much of ViroPharma’s Q1 call was spent on discussing updated clinical data for maribavir, an experimental treatment for human cytomegalovirus (also known as HMCV) in hematopoietic stem cell and bone marrow transplant patients. HCMV, which is often undetected by healthy people, has the potential to be fatal in patients with compromised immune systems, leading to a variety of CMV-induced illnesses, such as CMV hepatitis, CMV pneumonitis, and CMV esophagitis. ViroPharma has been testing maribavir in Europe (and currently has several named patient programs in place), and data presented on the company’s Q1 call is encouraging. There are currently two Phase II trials of maribavir (for both stem cell and bone marrow transplants), and viral clearance has been achieved in over 90% of (over 37 out of 41) patients in these trials. Of note, these trials include patients that are refractory and/or resistant to current CMV treatments. Additionally, ViroPharma is conducting a 160-patient European trial of maribavir in asymptomatic CMV viremia; the trial includes 3 dosing arms and is a head-to-head trial comparing maribavir to Roche’s Valcyte (valganciclovir), and another 120-patient U.S. study as well. Preliminary data from these various studies has been positive, with 26 out of 28 (93%) patients for whom data is available in the asymptomatic study showing viral clearance (as measured by CMV levels in their plasma). Of the 2 patients that failed to show clearance, only 1 was tied to maribavir, with the other patient being forced to withdraw from the study for non-medical reasons. Data for the Valcyte arm, however, is also made less clear by patient withdrawals. Viral clearance was achieved in 5 out of 8 patients (53%), but these 3 subjects were all withdrawn from the study for non-medical reasons. Within the resistant & refractory study, 12 out of 13 (92%) patients for whom data is available showed viral clearance. The 13t